NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Clinical trial NCT06781281 · RECRUITING

Trial details

NCT number: NCT06781281
Sponsor: Henan Cancer Hospital
Status: RECRUITING
Study type: OBSERVATIONAL

Breast Cancer Invasive

Start date: 2024-12-04
Primary completion: 2026-11-28
Enrollment: 709

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.